This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (30)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Combined Effects in Previously Untreated Normal Subjects

Timo Koskela, MD; Richard F. Brubaker, MD

Arch Ophthalmol. 1991;109(6):804-806.

Abstract
• Twenty healthy subjects were tested for the aqueous-suppressing effects of the ₂-adrenergic agonist apraclonidine hydrochloride. Apraclonidine caused a 30% reduction of mean (±SD) aqueous flow during the daytime from 2.84±0.61 µL/min, similar to what has been observed for β-adrenergic antagonists. Apraclonidine, like acetazolamide and unlike timolol maleate, was able to suppress the aqueous flow of sleeping subjects below the spontaneous nocturnal rate of 1.15±0.40 µL/min to 0.84±0.28 µL/min, a 27% change. When apraclonidine and timolol were given together in the daytime, no clinically significant or statistically significant additive effect was observed. The range of flows with either drug alone or the combination of the two measured from 2 to 4 PM was 1.41 to 1.78 µL/min. This result contrasts with studies of the effect of apraclonidine on patients who have received long-term β-blockers where an additive effect is observed. The lack of an additive effect on flow in previously untreated normal subjects suggests that the two drugs act at least in part via a common pathway.

Author Affiliations
From the Department of Ophthalmology, University of Umea, Umea, Sweden (Dr Koskela) and the Department of Ophthalmology, Mayo Clinic, Rochester, Minn (Dr Brubaker).

Footnotes
Accepted for publication February 1, 1991.

Reprint requests to Department of Ophthalmology, Mayo Clinic, 200 First St SW, Rochester, MN 55905 (Dr Brubaker).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Evaluation of the beta2-Adrenergic Receptor Gene as a Candidate Glaucoma Gene in 2 Ancestral Populations
McLaren et al.
Arch Ophthalmol 2007;125:105-111.
ABSTRACT | FULL TEXT  

Effect of cAMP on Porcine Ciliary Transepithelial Short-Circuit Current, Sodium Transport, and Chloride Transport
Ni et al.
IOVS 2006;47:2065-2074.
ABSTRACT | FULL TEXT  

The Effect of Latanoprost, Brimonidine, and a Fixed Combination of Timolol and Dorzolamide on Circadian Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension
Orzalesi et al.
Arch Ophthalmol 2003;121:453-457.
ABSTRACT | FULL TEXT  

Aqueous Humor Flow in Normal Human Eyes Treated With Brimonidine and Timolol, Alone and in Combination
Larsson
Arch Ophthalmol 2001;119:492-495.
ABSTRACT | FULL TEXT  

Effect of Timolol, Latanoprost, and Dorzolamide on Circadian IOP in Glaucoma or Ocular Hypertension
Orzalesi et al.
IOVS 2000;41:2566-2573.
ABSTRACT | FULL TEXT  

Comparison of the Early Effects of Brimonidine and Apraclonidine as Topical Ocular Hypotensive Agents
Maus et al.
Arch Ophthalmol 1999;117:586-591.
ABSTRACT | FULL TEXT  

Assessment of Ocular Hypotensive Mechanisms and Additivity of Antiglaucoma Drugs in Humans
Kaufman
Arch Ophthalmol 1999;117:673-674.
FULL TEXT  

Comparison of the Efficacy of Apraclonidine and Brimonidine as Aqueous Suppressants in Humans
Schadlu et al.
Arch Ophthalmol 1998;116:1441-1444.
ABSTRACT | FULL TEXT  

Comparison of Dorzolamide and Timolol as Suppressors of Aqueous Humor Flow in Humans
Wayman et al.
Arch Ophthalmol 1997;115:1368-1371.
ABSTRACT  

Effects of Brimonidine on Aqueous Humor Dynamics in Human Eyes
Toris et al.
Arch Ophthalmol 1995;113:1514-1517.
ABSTRACT  

Questions Concerning the Role of Apraclonidine in the Management of Glaucoma
Robin
Arch Ophthalmol 1995;113:712-714.
ABSTRACT